{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:45:00Z","timestamp":1770695100301,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016730","name":"Torii Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nobelpharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepcidin-25 plays an important role in regulating iron metabolism; however, the association between hepcidin-25 levels and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is controversial. We aimed to clarify the associations between serum hepcidin-25 levels and hyporesponsiveness to ESAs in Japanese patients receiving hemodialysis, and between hepcidin-25 levels and other factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observational cross-sectional study included hemodialysis patients recruited at Heisei-Hidaka Clinic in Japan from August 2023 to June 2024. Serum hepcidin-25 levels were measured by latex immunoassay. Hyporesponsiveness to ESAs was determined by the ESA resistance index (ERI). The correlation between hepcidin-25 levels and ERI was evaluated using Pearson\u2019s correlation coefficient. We also investigated the patient characteristics associated with hepcidin-25 levels using multiple regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Hepcidin-25 levels were significantly negatively correlated with ERI (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009= \u2212\u20090.438,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0005). Hepcidin-25 levels also showed significant positive correlations with serum iron, transferrin saturation (TSAT), serum ferritin, and high sensitive C-reactive protein (hs-CRP), and significant negative correlations with hematocrit, unsaturated iron-binding capacity, total iron-binding capacity, and serum erythropoietin levels. Hepcidin-25 levels were significantly higher in the patients who received oral iron-containing preparations than in those without these preparations. Multiple regression analysis showed significant partial regression coefficients for ERI, hematocrit, TSAT, serum ferritin, hs-CRP, and the administration of oral iron-containing preparations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum hepcidin-25 levels were significantly negatively correlated with the ERI. The results suggest that hepcidin-25 levels might be associated with ERI, hematocrit, TSAT, serum ferritin, hs-CRP, and the administration of oral iron-containing preparations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-025-02783-9","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:25:31Z","timestamp":1761899131000},"page":"348-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between serum hepcidin-25 levels and hyporesponsiveness to erythropoiesis-stimulating agents in Japanese patients receiving hemodialysis: a cross-sectional study"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4763-3588","authenticated-orcid":false,"given":"Ryo","family":"Fujikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6527-3286","authenticated-orcid":false,"given":"Nobuo","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8897-8561","authenticated-orcid":false,"given":"Yuko","family":"Mitobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2783_CR1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631\u20134.","journal-title":"J Am Soc Nephrol"},{"key":"2783_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1053\/j.ajkd.2008.12.040","volume":"53","author":"K Kalantar-Zadeh","year":"2009","unstructured":"Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53:823\u201334.","journal-title":"Am J Kidney Dis"},{"key":"2783_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000438870","volume":"131","author":"M Kimachi","year":"2015","unstructured":"Kimachi M, Fukuma S, Yamazaki S, et al. Minor elevation in C-reactive protein levels predicts incidence of erythropoiesis-stimulating agent hyporesponsiveness among hemodialysis patients. Nephron. 2015;131:123\u201330.","journal-title":"Nephron"},{"key":"2783_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1053\/j.ajkd.2011.07.014","volume":"59","author":"S Fukuma","year":"2012","unstructured":"Fukuma S, Yamaguchi T, Hashimoto S, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis. 2012;59:108\u201316.","journal-title":"Am J Kidney Dis"},{"key":"2783_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.kint.2017.02.035","volume":"92","author":"M Sugahara","year":"2017","unstructured":"Sugahara M, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017;92:306\u201312.","journal-title":"Kidney Int"},{"key":"2783_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jhep.2008.09.018","volume":"50","author":"B Gagliardo","year":"2009","unstructured":"Gagliardo B, Kubat N, Faye A, et al. Pro-hepcidin is unable to degrade the iron exporter ferroportin unless maturated by a furin-dependent process. J Hepatol. 2009;50:394\u2013401.","journal-title":"J Hepatol"},{"key":"2783_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.ajkd.2009.12.030","volume":"55","author":"JL Babitt","year":"2010","unstructured":"Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010;55:726\u201341.","journal-title":"Am J Kidney Dis"},{"key":"2783_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1159\/000521162","volume":"8","author":"HHL Wu","year":"2022","unstructured":"Wu HHL, Chinnadurai R. Erythropoietin-stimulating agent hyporesponsiveness in patients living with chronic kidney disease. Kidney Dis. 2022;8:103\u201314.","journal-title":"Kidney Dis"},{"key":"2783_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.medici.2017.03.001","volume":"53","author":"K Petrulien\u0117","year":"2017","unstructured":"Petrulien\u0117 K, \u017diginskien\u0117 E, Kuzminskis V, Nedzelskien\u0117 I, Bumblyt\u0117 IA. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Medicina (Kaunas). 2017;53:90\u2013100.","journal-title":"Medicina (Kaunas)"},{"key":"2783_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11255-018-2062-z","volume":"51","author":"DA El Sewefy","year":"2019","unstructured":"El Sewefy DA, Farweez BA, Behairy MA, Yassin NR. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients. Int Urol Nephrol. 2019;51:325\u201334.","journal-title":"Int Urol Nephrol"},{"key":"2783_CR11","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.3109\/0886022X.2013.828267","volume":"35","author":"M do Sameiro-Faria","year":"2013","unstructured":"do Sameiro-Faria M, Ribeiro S, Rocha-Pereira P, et al. Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. Ren Fail. 2013;35:1392\u20138.","journal-title":"Ren Fail"},{"key":"2783_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/1744-9987.70040","volume":"29","author":"T Matsuoka","year":"2025","unstructured":"Matsuoka T, Tomita H, Tagami T, et al. Limited utility of serum hepcidin as a marker for erythropoiesis-stimulating agent hyporesponsiveness in hemodialysis patients: an analysis from the INFINITY cohort. Ther Apher Dial. 2025;29:620\u20138.","journal-title":"Ther Apher Dial"},{"key":"2783_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13896","volume":"9","author":"D Kamei","year":"2023","unstructured":"Kamei D, Nagano M, Takagaki T, Sakamoto T, Tsuchiya K. Comparison between liquid chromatography\/tandem mass spectroscopy and a novel latex agglutination method for measurement of hepcidin-25 concentrations in dialysis patients with renal anemia: a multicenter study. Heliyon. 2023;9:e13896.","journal-title":"Heliyon"},{"key":"2783_CR14","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1373\/clinchem.2016.256768","volume":"62","author":"LN van der Vorm","year":"2016","unstructured":"van der Vorm LN, Hendriks JC, Laarakkers CM, et al. Toward worldwide hepcidin assay harmonization: identification of a commutable secondary reference material. Clin Chem. 2016;62:993\u20131001.","journal-title":"Clin Chem"},{"key":"2783_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000253590","volume":"122","author":"E Costa","year":"2009","unstructured":"Costa E, Swinkels DW, Laarakkers CM, et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol. 2009;122:226\u20139.","journal-title":"Acta Haematol"},{"key":"2783_CR16","doi-asserted-by":"publisher","first-page":"13779","DOI":"10.3390\/ijms241813779","volume":"24","author":"N Tomosugi","year":"2023","unstructured":"Tomosugi N, Koshino Y, Ogawa C, et al. Oral iron absorption of ferric citrate hydrate and hepcidin-25 in hemodialysis patients: a prospective, multicenter, observational Riona-Oral iron absorption trial. Int J Mol Sci. 2023;24:13779.","journal-title":"Int J Mol Sci"},{"key":"2783_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/ki.2009.21","volume":"75","author":"DR Ashby","year":"2009","unstructured":"Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75:976\u201381.","journal-title":"Kidney Int"},{"key":"2783_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.33549\/physiolres.930841","volume":"55","author":"M Vokurka","year":"2006","unstructured":"Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006;55:667\u201374.","journal-title":"Physiol Res"},{"key":"2783_CR19","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271\u20136.","journal-title":"J Clin Invest"},{"key":"2783_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039783","volume":"7","author":"NC van der Weerd","year":"2012","unstructured":"van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS ONE. 2012;7:e39783.","journal-title":"PLoS ONE"},{"key":"2783_CR21","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000312381","volume":"31","author":"T Kuragano","year":"2010","unstructured":"Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31:534\u201340.","journal-title":"Am J Nephrol"},{"key":"2783_CR22","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1365-2362.2009.02182.x","volume":"39","author":"G Weiss","year":"2009","unstructured":"Weiss G, Theurl I, Eder S, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009;39:883\u201390.","journal-title":"Eur J Clin Invest"},{"key":"2783_CR23","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1182\/blood-2005-10-4043","volume":"108","author":"N Tomosugi","year":"2006","unstructured":"Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidin in renal failure and inflammation by using proteinchip system. Blood. 2006;108:1381\u20137.","journal-title":"Blood"},{"key":"2783_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1159\/000517053","volume":"7","author":"T Akizawa","year":"2021","unstructured":"Akizawa T, Nangaku M, Yamaguchi T, et al. A phase 3 study of Enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study. Kidney Diseases. 2021;7:494\u2013502.","journal-title":"Kidney Diseases"},{"key":"2783_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1159\/000089266","volume":"25","author":"J Ma\u0142yszko","year":"2005","unstructured":"Ma\u0142yszko J, Ma\u0142yszko JS, Hryszko T, Pawlak K, Mysliwiec M. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients? Am J Nephrol. 2005;25:586\u201390.","journal-title":"Am J Nephrol"},{"issue":"7","key":"2783_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","volume":"46","author":"L Kautz","year":"2014","unstructured":"Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678\u201384 ([Erratum. In: Nat Genet. 2020;52:463.]).","journal-title":"Nat Genet"},{"key":"2783_CR27","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1172\/JCI32701","volume":"117","author":"I De Domenico","year":"2007","unstructured":"De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Invest. 2007;117:1755\u20138.","journal-title":"J Clin Invest"},{"key":"2783_CR28","doi-asserted-by":"crossref","unstructured":"Murata T, Fukuoka T, Fujii T, Yujiri T. Hepcidin values can help predict the responsiveness of roxadustat for treating anemia in patients with chronic kidney disease. Lab Med. 2025;ahead of print.","DOI":"10.1093\/labmed\/lmaf005"},{"key":"2783_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100865","volume":"75","author":"NU Stoffel","year":"2020","unstructured":"Stoffel NU, von Siebenthal HK, Moretti D, Zimmermann MB. Oral iron supplementation in iron-deficient women: how much and how often? Mol Aspects Med. 2020;75:100865.","journal-title":"Mol Aspects Med"},{"issue":"Suppl 7","key":"2783_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ndt\/16.suppl_7.25","volume":"16","author":"T Dr\u00fceke","year":"2001","unstructured":"Dr\u00fceke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant. 2001;16(Suppl 7):25\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"2783_CR31","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","volume":"306","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090\u20133.","journal-title":"Science"},{"key":"2783_CR32","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","volume":"117","author":"T Ganz","year":"2011","unstructured":"Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425\u201333.","journal-title":"Blood"},{"key":"2783_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000336482","volume":"2","author":"BV Stef\u00e1nsson","year":"2012","unstructured":"Stef\u00e1nsson BV, Abramson M, Nilsson U, Haraldsson B. Hemodiafiltration improves plasma 25-hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration. Nephron Extra. 2012;2:55\u201365.","journal-title":"Nephron Extra"},{"key":"2783_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12882-021-02543-3","volume":"22","author":"T Tomo","year":"2021","unstructured":"Tomo T, Larkina M, Shintani A, et al. Changes in practice patterns in Japan from before to after JSDT 2013 guidelines on hemodialysis prescriptions: results from the JDOPPS. BMC Nephrol. 2021;22:339.","journal-title":"BMC Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02783-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02783-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02783-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:28:34Z","timestamp":1770629314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02783-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2783"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02783-9","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ryo Fujikawa and Yuko Mitobe are employees of Torii Pharmaceutical Co., Ltd. Nobuo Nagano has received honoraria for lectures on anemia from Kyowa Kirin CO., Ltd, Nobelpharma Co., Ltd, and Torii Pharmaceuticals Co., Ltd. Kyoko Ito has no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Ethical Guidelines for Medical and Biological Research Involving Human Subjects. The protocol was approved by the Review Board of Human Rights and Ethics for Clinical Studies Ethics Review Committee (approval number: E2023-04\u2013001). All procedures involving human participants were conducted in accordance with the ethical standards of the Hidaka Hospital Medical Ethics Committee (approval number: 373).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All study participants provided written informed consent before undergoing study procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}